Research Feeds

View All
Maternal Iron Deficiency Anemia Affects Postpartum Emotions and Cognition Evidence for the Use of Complementary and Alternative Medicine for Pelvic Inflammatory Disease: A Literature Review Pelvic inflammatory disease: a family practice perspective Microbiology profile in women with pelvic inflammatory disease in relation to IUD use Epidermiological markers in pelvic inflammatory disease (PID) among the women of reproductive age group Bacterial isolates associated with pelvic inflammatory disease among female patients attending some hospitals in abuja, Nigeria The Key Element Role of Metallophores in the Pathogenicity and Virulence of Staphylococcus aureus: A Review The relationship between serum calprotectin levels and disease activity in patients with subacute thyroiditis. 919 Syrup Alleviates Postpartum Depression by Modulating the Structure and Metabolism of Gut Microbes and Affecting the Function of the Hippocampal GABA/Glutamate System Gut microbiota: Linking nutrition and perinatal depression The role of gut microbiota and blood metabolites in postpartum depression: A Mendelian randomization analysis. Association between dietary trace minerals and pelvic inflammatory disease: Data from the 2015–2018 National Health and Nutrition Examination Surveys Association between dietary magnesium intake and pelvic inflammatory disease in US women: a cross-sectional study of NHANES Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease Treatment of postpartum depression: Clinical, psychological and pharmacological options

The Positive Influence of Polyphenols Extracted From Pueraria lobata Root on the Gut Microbiota and Its Antioxidant Capability Original paper

Researched by:

  • Karen Pendergrass ID

March 18, 2025

Researched by:

  • Karen Pendergrass ID

Last Updated: 2024

Karen Pendergrass

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

What Was Studied?

This study examined the effects of a polyphenol-rich extract derived from Pueraria lobata (commonly known as kudzu root) on gut microbiota composition and antioxidant activity in both in vitro and in vivo models. Using antioxidant assays and high-throughput sequencing, the researchers investigated the extract’s ability to modulate oxidative stress and alter microbial populations in the gut.

Who Was Studied?

The in vivo experiments involved male C57BL/6 mice divided into control and experimental groups. The experimental group received a daily dose of 200 mg/kg of the P. lobata extract for 30 days, while the control group received water. Fecal samples were collected for gut microbiota analysis, and liver tissue was assessed for oxidative stress markers.

What Were the Most Important Findings?

The study demonstrated that the Pueraria lobata extract significantly improved antioxidant status and gut microbiota composition in mice. It enhanced key antioxidant enzyme activities, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and reduced markers of oxidative stress like malondialdehyde (MDA). In terms of gut microbiota, the extract increased beneficial taxa (e.g., Lactobacillaceae, Bacteroidetes, and Rikenellaceae) while suppressing harmful families (e.g., Ruminococcaceae, Prevotellaceae, and Burkholderiaceae). These changes included favorable shifts in the Firmicutes-to-Bacteroidetes ratio, a crucial metric for metabolic and immune health. Functional analyses predicted alterations in cellular and neurological health pathways, underscoring the systemic effects of gut microbiota modulation by the extract.

Antioxidant Effects of P. lobata Extract

ParameterChange Observed
Superoxide dismutase (SOD)Increased by 25.7%
Glutathione peroxidase (GSH-Px)Increased by 21.6%
Total antioxidant capacity (T-AOC)Increased by 13.6%
Malondialdehyde (MDA)Reduced by 33.9%

Gut Microbiota Effects of P. lobata Extract

TaxaChange Observed
LactobacillaceaeIncreased 1.64-fold
BacteroidetesIncreased 3.96-fold
RikenellaceaeIncreased 2.02-fold
RuminococcaceaeDecreased by 66.8%
PrevotellaceaeDecreased by 23.3%
BurkholderiaceaeDecreased by 73.6%
ErysipelotrichaceaeMarkedly reduced (>90%)
AkkermansiaceaeMarkedly reduced (>90%)

What Are the Greatest Implications of This Study?

The findings suggest that Pueraria lobata extract could serve as a natural antioxidant and prebiotic, offering potential applications in managing oxidative stress-related conditions and gut dysbiosis. Its ability to selectively enhance beneficial microbes and suppress harmful ones makes it a promising candidate for developing functional foods or therapeutic interventions for chronic diseases such as metabolic syndrome, obesity, and neurodegenerative disorders. Additionally, the observed dual benefits of antioxidative and gut microbiota modulation highlight its multifaceted therapeutic potential.

Join the Roundtable

Contribute to published consensus reports, connect with top clinicians and researchers, and receive exclusive invitations to roundtable conferences.

Karen Pendergrass

User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

Karen Pendergrass

User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

Karen Pendergrass

User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.